On September 27, 2023 Lunit (KRX:328130.KQ), a leading provider of AI-powered solutions for cancer diagnostics and therapeutics, reported the presentation of 6 abstracts featuring its Lunit SCOPE suite at the upcoming SITC (Free SITC Whitepaper) 2023 (Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper) 2023) Annual Meeting, scheduled to take place from November 1 to November 5, in San Diego, California (Press release, Lunit, SEP 27, 2023, View Source [SID1234635473]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
This year’s posters span a spectrum of research, from predicting treatment outcomes in non-small cell lung cancer (NSCLC) to examining immune responses in breast cancer subtypes, utilizing the Lunit SCOPE suite.
The highlighted abstracts for SITC (Free SITC Whitepaper) 2023 include:
By analyzing the tumor microenvironment (TME) with Lunit SCOPE IO, one study explores the treatment response of non-small cell lung cancer (NSCLC) patients with EGFR mutations to immune checkpoint inhibitors (ICI) after acquiring resistance to EGFR tyrosine kinase inhibitors (TKI).
Lunit investigates the distribution of tumor-infiltrating lymphocytes (TIL) in triple-negative breast cancer (TNBC) subtypes and their association with driver mutations, shedding light on the complexities of TNBC treatment response.
Lunit delves into the relationship between methylation and cancer immunogenicity across multiple cancer types.
A study examines the influence of tumor fragmentation index (TFI) and fibroblast infiltration on inflammatory cytokines, and lymphocyte maturation in the tumor microenvironment across various carcinoma cancer types.
Lunit introduces an innovative approach to assess immune phenotype (IP) in tumor tissue using AI-powered analysis of PD-L1 IHC whole-slide images.
An additional presentation provides updated safety and efficacy results for a novel PD-1 (programmed cell death 1) agent, assessed by Lunit SCOPE IO.
"We are truly excited to showcase the capabilities of Lunit SCOPE products in assessing pathology data, improving our ability to identify responsive patients and understand cancer biology," said Brandon Suh, CEO of Lunit. "These study results promise to advance our understanding of the tumor microenvironment, paving the way for increasingly tailored and more effective cancer therapies."
Visit Lunit’s booth at SITC (Free SITC Whitepaper) 2023 at Booth 227 to learn more about these pioneering studies. To schedule a meeting with the Lunit team, please reach out to [email protected].